RxDoctor Payments Data

Arnel Joaquin, MD

Internal Medicine · Los Angeles, CANPI 1720032980

Payments from drug & device makers

$318,532in general payments, 2019–2025

Across 15 payments — averaging $21,235 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$285K
  • Novartis$33K
  • Boehringer Ingelheim$74
$1,250in research payments, 2019–2025

Across 1 payment — averaging $1250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$1K

What the payments were for

  • Food & beverage$74100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi Pasteur Inc.11$285,476
Novartis3$32,983
Boehringer Ingelheim1$74

How this compares

$318,532 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$4,123
Medicare patients
21
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate36$48,057
JardianceEmpagliflozin57$43,408
Invega SustennaPaliperidone Palmitate12$36,901
EliquisApixaban51$29,036
JanuviaSitagliptin Phosphate32$16,657
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,347
Breo ElliptaFluticasone/Vilanterol33$13,880
Olanzapine OdtOlanzapine121$13,142
Diclofenac Sodium21$12,650
Aripiprazole89$12,050
FarxigaDapagliflozin Propanediol21$11,661
MyrbetriqMirabegron21$10,011
OzempicSemaglutide11$8,959
VascepaIcosapent Ethyl34$8,888
EntrestoSacubitril/Valsartan12$8,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$74$50,23369 claims
NovartisEntresto$32,983$8,54712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →